Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding Due to Trauma

Novo Nordisk A/S

Overview

This trial is conducted in the United States of America (USA). The purpose of this study is to evaluate the treatment of Recombinant Faction VIIa in Patients with Severe Bleeding Due to Trauma Please note that this trial and trial F7TRAUMA-1711 (NCT00184548) have been merged.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Conditions

Acquired Bleeding Disorder Trauma

Interventions

activated recombinant human factor VIIDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Trauma injury (blunt and/or penetrating) with evidence of active torso hemorrhage refectory to standard treatment

Locations (42)

Outcomes

Primary Outcomes

Mortality and Morbidity

Time frame: through day 30

Secondary Outcomes

All cause mortality

Hospital-free days

Number of transfusion units

Days free of renal replacement therapy

ICU-free days

Days free of ventilator support

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.